ATE470151T1 - Diagnose, behandlung und prävention von gefässerkrankungen mittels il-1alpha- autoantikörpern - Google Patents

Diagnose, behandlung und prävention von gefässerkrankungen mittels il-1alpha- autoantikörpern

Info

Publication number
ATE470151T1
ATE470151T1 AT06795161T AT06795161T ATE470151T1 AT E470151 T1 ATE470151 T1 AT E470151T1 AT 06795161 T AT06795161 T AT 06795161T AT 06795161 T AT06795161 T AT 06795161T AT E470151 T1 ATE470151 T1 AT E470151T1
Authority
AT
Austria
Prior art keywords
autoantibodies
vascular disease
1alpha
diagnosis
prevention
Prior art date
Application number
AT06795161T
Other languages
English (en)
Inventor
John Simard
Klaus Bendtzen
Original Assignee
Xbiotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xbiotech Inc filed Critical Xbiotech Inc
Application granted granted Critical
Publication of ATE470151T1 publication Critical patent/ATE470151T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Rehabilitation Therapy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT06795161T 2005-08-02 2006-07-26 Diagnose, behandlung und prävention von gefässerkrankungen mittels il-1alpha- autoantikörpern ATE470151T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70445005P 2005-08-02 2005-08-02
PCT/IB2006/002038 WO2007015128A1 (en) 2005-08-02 2006-07-26 DIAGNOSIS, TREATMENT, AND PREVENTION OF VASCULAR DISORDERS USING IL-1α AUTOANTIBODIES

Publications (1)

Publication Number Publication Date
ATE470151T1 true ATE470151T1 (de) 2010-06-15

Family

ID=37442093

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06795161T ATE470151T1 (de) 2005-08-02 2006-07-26 Diagnose, behandlung und prävention von gefässerkrankungen mittels il-1alpha- autoantikörpern

Country Status (11)

Country Link
US (2) US8187817B2 (de)
EP (2) EP1915620B1 (de)
JP (2) JP5645361B2 (de)
CN (2) CN101253409A (de)
AT (1) ATE470151T1 (de)
AU (1) AU2006274698B2 (de)
CA (1) CA2617637C (de)
DE (1) DE602006014691D1 (de)
DK (1) DK1915620T3 (de)
ES (1) ES2346691T3 (de)
WO (1) WO2007015128A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2617637C (en) * 2005-08-02 2017-07-18 Xbiotech Inc. Diagnosis, treatment, and prevention of vascular disorders using il-1.alpha. autoantibodies
WO2007132338A2 (en) 2006-05-15 2007-11-22 Xbiotech Inc. IL-1α IMMUNIZATION INDUCES AUTOANTIBODIES PROTECTIVE AGAINST ATHEROSCLEROSIS
US20110008282A1 (en) * 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
US20100040574A1 (en) * 2006-05-22 2010-02-18 Xbiotech Inc. TREATMENT OF CANCER WITH ANTI-IL-1alpha ANTIBODIES
EP2285409B1 (de) * 2008-05-30 2016-04-20 XBiotech, Inc Il-1-alpha-antikörper
CA2737056C (en) * 2008-09-12 2018-10-30 Xbiotech Inc. Targeting pathogenic monocytes
EP2569640A1 (de) 2010-05-12 2013-03-20 The University of Birmingham Biomarker
AR081246A1 (es) 2010-05-14 2012-07-18 Abbott Lab Proteinas de union a il-1
EP2582391B1 (de) 2010-06-18 2018-10-03 XBiotech, Inc Arthritis-behandlung
KR101910760B1 (ko) 2010-08-23 2018-10-22 엑스바이오테크, 인크. 종양성 질병들에 대한 치료
JP5904553B2 (ja) * 2010-11-17 2016-04-13 国立大学法人愛媛大学 自己免疫疾患に関与するタンパク質の解析方法及び該疾患の検査方法
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
CN108404127B (zh) 2011-09-23 2025-12-12 埃克斯生物科技公司 恶病质治疗
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
EP3582813A4 (de) 2017-02-16 2020-12-30 XBiotech, Inc Behandlung von hidradenitis suppurativa
CA3093469A1 (en) * 2018-03-09 2019-09-12 The Brigham And Women's Hospital, Inc. Combination therapy for cardiovascular diseases
US10975146B2 (en) 2018-06-29 2021-04-13 Cedars-Sinai Medical Center Interleukin-1 inhibition for combination treatment of pancreatic cancer
KR20220019674A (ko) * 2019-05-03 2022-02-17 유니베르시태트 취리히 뇌 허혈-재관류 손상의 치료
CA3095679A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleuken 1 alpha (il-1a)
CA3095740A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin alpha (il-1a)
CA3095676A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
CA3095675A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
JP2023173360A (ja) * 2022-05-25 2023-12-07 日本メナード化粧品株式会社 生体老化レベルの評価方法

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) * 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US5168062A (en) * 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4965198A (en) * 1985-12-24 1990-10-23 Konica Corporation Monoclonal antibody and method of manufacturing hybridoma producing the same
DE3631229A1 (de) * 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
DK590387A (da) 1986-11-13 1988-05-14 Otsuka Pharma Co Ltd Antistoffer mod interleukin-1
US5034316A (en) * 1987-03-30 1991-07-23 The Regents Of The University Of California In vitro human monoclonal IgG rheumatoid factor autoantibody
FR2640146B1 (fr) 1988-12-08 1993-12-24 Commissariat A Energie Atomique Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0434879A1 (de) 1989-12-14 1991-07-03 Schering-Plough Verfahren zur Herstellung von faktorabhÀ¤ngigen menschlichen B-Zellinien
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
ES2140469T3 (es) * 1992-10-14 2000-03-01 Nycomed Imaging As Composiciones y metodos terapeuticos y de diagnostico por obtencion de imagenes.
DE69427928T3 (de) * 1993-03-05 2012-05-10 Bayer Healthcare Llc Humane monoklonale anti-TNF alpha Antikörper
EP0659766A1 (de) 1993-11-23 1995-06-28 Schering-Plough Menschliche Monoklonalantikörper gegen menschliche Cytokine und Verfahren zur Herstellung dieser Antikörper
US5959085A (en) 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
GB9509620D0 (en) 1995-05-12 1995-07-05 Nat Blood Authority Transepithelial transport of molecular species
WO1997002479A2 (en) * 1995-06-30 1997-01-23 Yale University Human monoclonal anti-tumor antibodies
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US6524795B1 (en) * 1997-03-10 2003-02-25 Interleukin Genetics, Inc. Diagnostics for cardiovascular disorders
SE9802402D0 (sv) * 1998-07-03 1998-07-03 Karolinska Innovations Ab Method of diagnosing cardiovascular disease and early atherosclerosis
US20030040617A9 (en) * 1999-03-12 2003-02-27 Rosen Craig A. Nucleic acids, proteins and antibodies
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US20030232054A1 (en) * 2000-01-25 2003-12-18 Tang Y. Tom Novel nucleic acids and polypeptides
US6623736B2 (en) * 2000-05-02 2003-09-23 Edward L. Tobinick Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
AU2001295442A1 (en) * 2000-10-17 2002-04-29 Besst-Test Aps Assay for directly detecting an inflammatory indicator in a body fluid sample
US20030026806A1 (en) * 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
JP2005510524A (ja) 2001-11-16 2005-04-21 アルス・セラピー・デベロツプメント・フアンデーシヨン・インコーポレーテツド ポリアミン経路の調節による神経変性障害の治療
KR101317045B1 (ko) * 2002-09-06 2013-10-16 암젠 인코포레이티드 치료학적 인체 항-ｉｌ-1ｒ1 모노클로날 항체
US20040224893A1 (en) 2003-05-06 2004-11-11 Li-Hsien Wang Methods of using IL-1 antagonists to treat neointimal hyperplasia
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
US7799327B2 (en) * 2003-12-24 2010-09-21 Henry John Smith Autoantibodies utilized as carrier agents for pharmaceutical compounds used in cancer treatment
US7105183B2 (en) * 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
US20050276807A1 (en) 2004-06-15 2005-12-15 Advanced Biotherapy, Inc. Treatment of acne
US7718674B2 (en) 2004-09-27 2010-05-18 Bridge Pharma, Inc. Methods of relieving neuropathic pain with the S-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine
US8603483B2 (en) 2004-12-09 2013-12-10 Janssen Biotech, Inc. Anti-integrin immunoconjugates, methods and uses
CA2617637C (en) * 2005-08-02 2017-07-18 Xbiotech Inc. Diagnosis, treatment, and prevention of vascular disorders using il-1.alpha. autoantibodies
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
NZ566971A (en) 2005-09-28 2011-06-30 Cytos Biotechnology Ag Vaccine containing a virus like particle linked with an interleukin-1 molecule
US20110008282A1 (en) * 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
WO2007132338A2 (en) 2006-05-15 2007-11-22 Xbiotech Inc. IL-1α IMMUNIZATION INDUCES AUTOANTIBODIES PROTECTIVE AGAINST ATHEROSCLEROSIS
US20100040574A1 (en) 2006-05-22 2010-02-18 Xbiotech Inc. TREATMENT OF CANCER WITH ANTI-IL-1alpha ANTIBODIES
EP2032606B1 (de) * 2006-05-30 2013-11-27 Genentech, Inc. Antikörper und immunkonjugate sowie ihre verwendungen
EP2114443A4 (de) 2006-12-29 2011-08-10 Abbott Lab Doppelt spezifische il-1a/il-1b-antikörper
WO2009128934A1 (en) 2008-04-15 2009-10-22 Sarcode Corporation Topical lfa-1 antagonists for use in localized treatment of immune related disorders
EP2285409B1 (de) 2008-05-30 2016-04-20 XBiotech, Inc Il-1-alpha-antikörper
CA2737056C (en) 2008-09-12 2018-10-30 Xbiotech Inc. Targeting pathogenic monocytes
EP2391652A4 (de) 2009-01-29 2013-01-02 Abbott Lab Il-1-bindende proteine

Also Published As

Publication number Publication date
JP2013127469A (ja) 2013-06-27
EP1915620A1 (de) 2008-04-30
EP2216653A1 (de) 2010-08-11
DK1915620T3 (da) 2010-10-04
CN109187944A (zh) 2019-01-11
AU2006274698A1 (en) 2007-02-08
JP5645361B2 (ja) 2014-12-24
EP1915620B1 (de) 2010-06-02
US8865175B2 (en) 2014-10-21
US8187817B2 (en) 2012-05-29
US20120231012A1 (en) 2012-09-13
JP5717256B2 (ja) 2015-05-13
ES2346691T3 (es) 2010-10-19
JP2009503529A (ja) 2009-01-29
DE602006014691D1 (de) 2010-07-15
AU2006274698B2 (en) 2011-06-09
WO2007015128A1 (en) 2007-02-08
AU2006274698A2 (en) 2008-03-06
US20090123415A1 (en) 2009-05-14
CA2617637A1 (en) 2007-02-08
CN101253409A (zh) 2008-08-27
CA2617637C (en) 2017-07-18

Similar Documents

Publication Publication Date Title
ATE470151T1 (de) Diagnose, behandlung und prävention von gefässerkrankungen mittels il-1alpha- autoantikörpern
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
EA200802204A1 (ru) Применение ингибиторов dpp iv
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
EA200971053A1 (ru) Способы лечения кожных язв
EA200870254A1 (ru) Способ лечения воспалительных заболеваний
EP2331095A4 (de) Bestimmte kynurenin-3-monooxygenase-inhibitoren, pharmazeutische zusammensetzungen und anwendungsverfahren dafür
EA201791669A3 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
DE60331236D1 (de) Orale zusammensetzungen zur behandlung von diabetes
BRPI0712322A2 (pt) compostos e combinações destes para a inibição da produção de beta-amilóide e métodos de uso dos mesmos
BRPI0814339A2 (pt) composição farmacêutica, kit para a preparação da composição farmacêutica, conjugado, e, métodos de formação de imagem óptica in vivo do corpo de mamíferos, e de detecção, estabilização, diagnóstico, monitoramento do progresso da doença ou monitoramento do tratamento de um estado doentio do corpon dos mamíferos
BRPI0821895A2 (pt) Composiçao farmacêutica, método de tratamento ou prevenção de uma doença, uma condição e sintomas das mesmas em animais de sangue quente, incluindo seres humanos, método de preparação da composição farmacêutica e método para diagnosticar uma doença, condição, síndrome.
EA201270071A1 (ru) Способ лечения пациента, нуждающегося в аспириновой терапии
CY1116938T1 (el) Αναπληρωτικη θεραπεια της ασθενειας huntington και αλλων ασθενειων πολυγλουταμiνης
NO20076405L (no) Anvendelse av 24-nor-UDCA
ATE371724T1 (de) Behandlung neurodegenerativer krankheiten
EP2005194A4 (de) Auf hämoglobin basierende verfahren zur prophylaxe, diagnose bzw. behandlung von netzhauterkrankungen
EP1744162A4 (de) Krebsdiagnose und behandlung unter verwendung eines anti-robo1-antikörpers
ATE485037T1 (de) Krebsbehandlung mittels fts und 2-deoxyglucose
ATE495271T1 (de) Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin
WO2006047475A3 (en) Detection and analysis of ophthalmically-relevant fluorescent molecules
EA201000739A1 (ru) Новое медицинское применение солей 3-(2,2,2-триметилгидразиниум)пропионата
BRPI0717306A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento, prevenção ou alívio de uma doença ou um distúrbio ou uma condição de um corpo de animal vivo.
ATE495750T1 (de) Sulfatide zur behandlung von autoimmunkrankheiten
CY1119845T1 (el) Ενα γαλακτοκομικο προϊον μειωμενης χοληστερολης για χρηση στην θεραπευτικη αντιμετωπιση και/ή προληψη μιας ασθενειας του ηπατος

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1915620

Country of ref document: EP